Key Points

  • iTTP in older patients has atypical clinical features delaying diagnosis; 1-month and 1-year mortality rates are higher.

  • A history of iTTP in older patients negatively impacts the life expectancy in survivors.

Abstract

Older age is associated with increased mortality in immune thrombotic thrombocytopenic purpura (iTTP). Yet, data are scarce regarding iTTP occurring among older patients. To assess clinical features and long-term impact of iTTP on mortality in older patients (>60 years old), characteristics and prognoses of adult iTTP patients enrolled in the French Reference Center for Thrombotic Microangiopathies registry between 2000 and 2016 were described according to age (<60 years old or ≥60 years old). Long-term mortality of iTTP older survivors was compared with that of non-iTTP geriatric subjects. Comparing, respectively, older iTTP patients (N = 71) with younger patients (N = 340), time from hospital admission to diagnosis was longer (P < .0001); at diagnosis, delirium (P = .034), behavior impairment (P = .045), renal involvement (P < .0001), and elevated troponin level (P = .025) were more important whereas cytopenias were less profound (platelet count, 22 × 103/mm3 [9-57] vs 13 × 103/mm3 [9-21], respectively [P = .002]; hemoglobin level, 9 g/dL [8-11] vs 8 g/dL [7-10], respectively [P = .0007]). Short- and mid-term mortalities were higher (P < .0001) and increased for every 10 years of age range. Age ≥60 years, cardiac involvement, increased plasma creatinine level, and total plasma exchange volume were independently associated with 1-month mortality. Compared with a non-iTTP geriatric population, older survivors showed an increased long-term mortality (hazard ratio = 3.44; P < .001). In conclusion, older iTTP patients have atypical neurological presentation delaying the diagnosis. Age negatively impacts short-term but also long-term mortality.

REFERENCES

REFERENCES
1.
Mariotte
E
,
Azoulay
E
,
Galicier
L
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy
.
Lancet Haematol
.
2016
;
3
(
5
):
e237
-
e245
.
2.
Sadler
JE
.
What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura
.
Hematology Am Soc Hematol Educ Program
.
2015
;
2015
:
631
-
636
.
3.
Dong
JF
,
Moake
JL
,
Nolasco
L
, et al
.
ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions
.
Blood
.
2002
;
100
(
12
):
4033
-
4039
.
4.
Benhamou
Y
,
Assié
C
,
Boelle
P-Y
, et al;
Thrombotic Microangiopathies Reference Center
.
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
.
Haematologica
.
2012
;
97
(
8
):
1181
-
1186
.
5.
Benhamou
Y
,
Boelle
P-Y
,
Baudin
B
, et al;
Experience of the French Thrombotic Microangiopathies Reference Center
.
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2015
;
13
(
2
):
293
-
302
.
6.
Sayani
FA
,
Abrams
CS
.
How I treat refractory thrombotic thrombocytopenic purpura
.
Blood
.
2015
;
125
(
25
):
3860
-
3867
.
7.
Scully
M
,
Cataland
SR
,
Peyvandi
F
, et al;
HERCULES Investigators
.
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2019
;
380
(
4
):
335
-
346
.
8.
Peyvandi
F
,
Scully
M
,
Kremer Hovinga
JA
, et al;
TITAN Investigators
.
Caplacizumab for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2016
;
374
(
6
):
511
-
522
.
9.
Goel
R
,
King
KE
,
Takemoto
CM
,
Ness
PM
,
Tobian
AA
.
Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012
.
Transfusion
.
2016
;
56
(
6
):
1451
-
1458
.
10.
Martino
S
,
Jamme
M
,
Deligny
C
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Thrombotic thrombocytopenic purpura in black people: impact of ethnicity on survival and genetic risk factors
.
PLoS One
.
2016
;
11
(
7
):
e0156679
.
11.
Jestin
M
,
Benhamou
Y
,
Schelpe
A-S
, et al;
French Thrombotic Microangiopathies Reference Center
.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
.
Blood
.
2018
;
132
(
20
):
2143
-
2153
.
12.
Deford
CC
,
Reese
JA
,
Schwartz
LH
, et al
.
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura
.
Blood
.
2013
;
122
(
12
):
2023
-
2029
,
quiz 2142
.
13.
Froissart
A
,
Buffet
M
,
Veyradier
A
, et al;
Experience of the French Thrombotic Microangiopathies Reference Center
.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange
.
Crit Care Med
.
2012
;
40
(
1
):
104
-
111
.
14.
Coppo
P
,
Schwarzinger
M
,
Buffet
M
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience
.
PLoS One
.
2010
;
5
(
4
):
e10208
.
15.
Scully
M
,
Cataland
S
,
Coppo
P
, et al;
International Working Group for Thrombotic Thrombocytopenic Purpura
.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
.
J Thromb Haemost
.
2017
;
15
(
2
):
312
-
322
.
16.
3C Study Group
.
Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population
.
Neuroepidemiology
.
2003
;
22
(
6
):
316
-
325
.
17.
Bendapudi
PK
,
Hurwitz
S
,
Fry
A
, et al
.
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
.
Lancet Haematol
.
2017
;
4
(
4
):
e157
-
e164
.
18.
Han
B
,
Page
EE
,
Stewart
LM
, et al
.
Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura
.
Am J Hematol
.
2015
;
90
(
8
):
709
-
714
.
19.
Widemann
A
,
Pasero
C
,
Arnaud
L
, et al;
ENDO-13 Study Group
.
Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study
.
J Thromb Haemost
.
2014
;
12
(
10
):
1601
-
1609
.
20.
Le Besnerais
M
,
Favre
J
,
Denis
CV
, et al
.
Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2016
;
14
(
10
):
1917
-
1930
.
21.
Xu
X
,
Wang
B
,
Ren
C
, et al
.
Recent progress in vascular aging: mechanisms and its role in age-related diseases
.
Aging Dis
.
2017
;
8
(
4
):
486
-
505
.
22.
Thorin
E
,
Thorin-Trescases
N
.
Vascular endothelial ageing, heartbeat after heartbeat
.
Cardiovasc Res
.
2009
;
84
(
1
):
24
-
32
.
23.
Barton
M
,
Cosentino
F
,
Brandes
RP
,
Moreau
P
,
Shaw
S
,
Lüscher
TF
.
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin
.
Hypertension
.
1997
;
30
(
4
):
817
-
824
.
24.
O’Rourke
MF
.
Arterial aging: pathophysiological principles
.
Vasc Med
.
2007
;
12
(
4
):
329
-
341
.
25.
Tokunaga
O
,
Yamada
T
,
Fan
JL
,
Watanabe
T
.
Age-related decline in prostacyclin synthesis by human aortic endothelial cells. Qualitative and quantitative analysis
.
Am J Pathol
.
1991
;
138
(
4
):
941
-
949
.
26.
Hodis
S
,
Zamir
M
.
Mechanical events within the arterial wall: the dynamic context for elastin fatigue
.
J Biomech
.
2009
;
42
(
8
):
1010
-
1016
.
27.
Peyvandi
F
,
Scully
M
,
Kremer Hovinga
JA
, et al
.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2017
;
15
(
7
):
1448
-
1452
.
28.
Christou
EAA
,
Giardino
G
,
Worth
A
,
Ladomenou
F
.
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab
.
Int Rev Immunol
.
2017
;
36
(
6
):
352
-
359
.
29.
Masias
C
,
Wu
H
,
McGookey
M
,
Jay
L
,
Cataland
S
,
Yang
S
.
No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry
.
Am J Hematol
.
2018
;
93
(
3
):
E73
-
E75
.
You do not currently have access to this content.